203 Pb AR RMX

Drug Profile

203 Pb AR RMX

Alternative Names: 203 Pb-AR-RMX-15

Latest Information Update: 17 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator AREVA Med; RadioMedix
  • Class Peptides; Radiopharmaceutical diagnostics
  • Mechanism of Action Single-photon emission-computed tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Clinical Phase Unknown Neuroendocrine tumours

Most Recent Events

  • 22 Jun 2017 Efficacy data from a clinical trial in Neuroendocrine tumours (Diagnosis) released by RadioMedix and AREVA Med
  • 31 May 2017 Clinical trials in Neuroendocrine tumours (Diagnosis) (Parenteral) before May 2017
  • 31 May 2017 Areva Med and RadioMedix complete a clinical trial in Neuroendocrine tumours (Diagnosis) in May 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top